Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 16/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5818377 | 0.92 | HTR1A (0.38) | HTR6HTR1AHTR1DHTR1B | |
| SCHEMBL5805845 | 0.83 | HTR2C (0.41) | — | |
| SCHEMBL5803260 | 0.83 | HTR2C (0.41) | — | |
| SCHEMBL5804656 | 0.82 | KDM4E (0.41) | HTR6 | |
| SCHEMBL5803267 | 0.80 | CA1 (0.38) | — | |
| Trifluoroacetic Acid SCHEMBL5819864 | 0.77 | HTR2C (0.41) | — | |
| Trifluoroacetic Acid SCHEMBL5955936 | 0.77 | HTR2C (0.41) | — | |
| SCHEMBL5803128 | 0.76 | HRH4 (0.41) | HTR6 | |
| Trifluoroacetic Acid SCHEMBL5814494 | 0.75 | KDM4E (0.37) | HTR6 | |
| SCHEMBL5803186 | 0.73 | HTR6 (0.49) | HTR6HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142269-A1 | New compounds | BIOVITRUM AB (SE) | 2006-06-29 | — | — | US | claimed |
| WO-2006062481-A1 | NEW BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS . | BIOVITRUM AB (SE) | 2006-06-15 | — | — | WO | claimed |
| US-20060142269-A1 | New compounds | BIOVITRUM AB (SE) | 2006-06-29 | — | — | US | disclosed |
| WO-2006062481-A1 | NEW BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS . | BIOVITRUM AB (SE) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142269-A1 | New compounds | GPR119, GLP1R, IAPP | DRD2 304/4885DRD3 310/4885HTR6 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.